Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes

NCT07770737 · tracked via the Priya Life Science South Korea tracker

Sponsor

Dongtan Sacred Heart Hospital

Phase

Observational

Started

2026-09

Last updated

2026-08-18

Condition(s) studied

Type 2 Diabetes Mellitus (T2DM)Cardiovascular DiseasesStage B Heart Failure

Study summary

This observational study will evaluate the cardiovascular effects of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) in Korean adults with type 2 diabetes.

The study consists of two phases. Phase 1 will use de-identified electronic health record data from multiple Korean hospitals organized in a common data model. Cardiovascular outcomes, including myocardial infarction, ischemic stroke, and hospitalization for heart failure, will be compared among patients who started an SGLT2 inhibitor or a GLP-1 receptor agonist. Fractures, metabolic changes, and real-world medication use will also be evaluated.

Phase 2 will prospectively enroll approximately 100 adults with type 2 diabetes who are starting an SGLT2 inhibitor as part of routine clinical care at Dongtan Sacred Heart Hospital. Participants will undergo electrocardiography, AI-based ECG analysis, echocardiography, blood and urine tests, and body composition assessment at baseline. Approximately 50 participants with stage B heart failure, defined as structural or functional heart abnormalities without heart failure symptoms, will undergo the same assessments after 6 months. The primary outcome of Phase 2 is the change in echocardiographic global longitudinal strain from baseline to 6 months. The study will also examine whether changes detected by AI-based ECG are associated with changes in echocardiographic measures of cardiac function.

The study does not assign medications or alter routine treatment. All treatment decisions are made by the participants' treating physicians.

Eligibility

Sex

ALL

Min age

19 Years

Max age

—

Healthy volunteers

Phase 1: Retrospective Cohorts Inclusion Criteria: * Adults aged 19 years or older. * Diagnosis of type 2 diabetes mellitus. * New initiation of a study medication, including an SGLT2 inhibitor, a GLP-1 receptor agonist, or another eligible glucose-lowering medication. * At least 180 days of observable data before the index date, defined as the date of the first eligible prescription. Exclusion Criteria: * Type 1 diabetes mellitus or secondary diabetes mellitus. * Use of a medication from the same drug class within 90 days before the index date. * Pregnancy recorded during the relevant study period. * A history of the outcome being evaluated during the baseline period, applied separately for each outcome analysis. Phase 2: Prospective SGLT2 Inhibitor Validation Cohort Inclusion Criteria: * Adults aged 50 years or older receiving outpatient care at Dongtan Sacred Heart Hospital. * Diagnosis of type 2 diabetes mellitus. * No current or previous signs or symptoms of heart failure and New York Heart Association functional class I. * At least one of the following high-risk characteristics: diabetes duration of 5 years or longer, hypertension, body mass index of 25 kg/m² or higher, urinary albumin-to-creatinine ratio of 30 mg/g or higher, estimated glomerular filtration rate below 60 mL/min/1.73 m², or diabetic microvascular complications. * No previous treatment with an SGLT2 inhibitor and scheduled to initiate an SGLT2 inhibitor based on the treating physician's clinical judgment. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Current or previous diagnosis of heart failure, hospitalization for heart failure, clinically suspected signs or symptoms of heart failure, or screening left ventricular ejection fraction below 50%. * Moderate or severe valvular heart disease, known hypertrophic, dilated, or infiltrative cardiomyopathy, complex congenital heart disease, or clinically significant pericardial disease. * Acute coronary syndrome, coronary revascularization, or stroke within 3 months before enrollment. * Presence of a pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy device. * Atrial fibrillation, sustained tachycardia, frequent premature contractions, or another arrhythmia that prevents reliable comparison of ECG or global longitudinal strain measurements. * Type 1 diabetes mellitus, secondary diabetes mellitus, diabetic ketoacidosis within the previous year, or another clinical condition making SGLT2 inhibitor treatment inappropriate. * Estimated glomerular filtration rate below 30 mL/min/1.73 m² or dialysis. * Echocardiographic image quality insufficient for reliable 3-view global longitudinal strain or stage B heart failure assessment. * Pregnancy or breastfeeding. * Unwillingness to undergo study assessments or inability to complete the 6-month follow-up.

Primary outcome measure(s)

Time to First Atherosclerotic Cardiovascular Disease Composite Event — From the index date until the first occurrence of acute myocardial infarction or ischemic stroke, loss to follow-up, death, or the end of available database records, whichever occurs first, assessed up to 12 years
Time from the index date to the first occurrence of acute myocardial infarction or ischemic stroke, identified using prespecified OMOP Common Data Model phenotype definitions. The outcome will be compared between treatment cohorts using hazard ratios with 95% confidence intervals.
Time to First Hospitalization for Heart Failure — From the index date until the first hospitalization for heart failure, loss to follow-up, death, or the end of available database records, whichever occurs first, assessed up to 12 years
Time from the index date to the first hospitalization accompanied by a diagnosis of heart failure, identified using prespecified OMOP Common Data Model phenotype definitions. The outcome will be compared between treatment cohorts using hazard ratios with 95% confidence intervals.
Change in Echocardiographic Global Longitudinal Strain — Baseline and 6 months after SGLT2 inhibitor initiation
Change in signed left ventricular global longitudinal strain from baseline to 6 months, calculated as GLS at 6 months minus GLS at baseline. A more negative change indicates improvement in left ventricular systolic function.

Trial sites (1)

Facility	City	Region	Status
Hallym University Dongtan Sacred Heart Hospital	Hwaseong-si	Gyeonggi-do

More Dongtan Sacred Heart Hospital trials in South Korea

Repetitive Transcranial Magnetic Stimulation in Patients With Hemiplegic Stroke Recruiting

Other trials for the same condition

Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes Recruiting

Identification of Risk Factors for Cardiovascular Disease and Cancer in Korean Population: A Prospective Cohort Study Recruiting

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) Active, not recruiting

Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes Active, not recruiting

Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07770737 on ClinicalTrials.gov ↗ ← All trials in South Korea